1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ARST0332, ARST0332, NCT00346164
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-302, NCT00538239
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: UCCRC-16227A, 16227A, 8131, NCT00720174
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: MSKCC-03099, NCT00077285
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: SARC-006, 006, NCI-06-C-0043, NCI-P6452, NCT00304083, UMN-2007CG077
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 014, NCT00503295
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-204, NCT00557609
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, NCT00668148
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
17.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-07-C-0040, NCI-P6981, NCT00428272
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 16
Sponsor: NCI
Protocol IDs: NCI-07-C-0054, NCT00437047
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2004-0079, NCT00502892
|
|
20.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-08-C-0007, 08-C-0007, NCI-P6068, 7458, NCT00556881
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: UMN-2005LS023, UMN-2005LS023, UMN-MT2004-30, NCT00623077
|
|
22.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: JHOC-J0685, NA_00003073, J0685, NCT00499733
|
